Supplementary Note
A total of 7,186 proteins were detected in TU, TAM and TAT (FDR=0.01 on the peptide and protein level, and minimum of 1 unique peptide per protein group), of which 6,442 proteins showed a median label-free quantification (LFQ) intensity >50 million (corresponding to the 0.25 quantile of the combined proteome). All TU, TAM and TAT samples showed a purity of >90% by microscopic or flow cytometry analysis. However, when analyzing the expression levels of multiple cell typeselective markers in our proteomic data, we found a significant contamination of 3 TAT samples with tumor proteins (see Supplementary Fig. 1a and Materials and Methods for details). We attribute this apparent discrepancy to the much larger size and thus higher protein content of TU relative to TAT. These TAT samples (Supplementary Table 1 ) were therefore excluded from analyses of cell type-selective expression, which would be distorted by TU protein contamination (see Materials and Methods for details). Principal component analysis (PCA) of the combined proteomes yielded a clear separation of TU, TAM and TAT samples ( Supplementary Fig. 1b ), indicating that the proteomic data were suitable for further in-depth analysis. To further illustrate statistically significant cell type-specific expression of proteins in TAM versus TU, TAT versus TU and TAT versus TAM, volcano plots were generated (Supplementary Fig. 1c and Supplementary Dataset 2). The top 30 genes with the highest selectivity for either of the cell types are depicted in Supplementary Fig. 1d . Gene ontology (GO) enrichment analyses of (i) TAT-specific proteins identified terms specific for T cell function, of (ii) TAM-specific proteins showed terms associated with macrophage function, and of (iii) TU-specific proteins revealed terms associated with cell growth, thus corroborating the validity of the proteomic analysis ( Supplementary Fig. 1e ).
In total, 7,186 proteins were identified in the proteomes. 7,100 proteins were undetectable in spite of readily detectable mRNA expression (49.7% detectable at TPM>2), while converse cases were comparably rare (n=125; 0.9%; Supplementary Fig. 2a , upper left panel; proteins with undetected mRNAs are listed in Supplementary Dataset 22). Such a detection of a protein without detection of the respective mRNA could be due to detection failure in mRNA sequencing or due to false positive detection in protein mass spectrometry (FDR filtration employed in this study is 1% on both the peptide and protein level). Supplementary Fig. 2a shows that that the overlap between transcriptomes and proteomes was considerably bigger (52.3%) for intracellular proteins (see Materials and Methods) compared to membrane or secreted proteins (37.7% and 43.2%, respectively). To identify the cause for the relatively low percentage of membrane and secreted proteins in the proteomes, we investigated the relationship between mRNA expression and the detection of the corresponding proteins. Genes encoding growth factor/cytokine receptors or their respective ligands, which were not detected by our proteomic analysis in spite of high TPM values, are shown in Supplementary Fig. 2b . To address the issue of discrepancies between transcriptome and proteome in more detail, we used flow cytometry to examine the expression of several proteins, which were present in the transcriptome, but absent from the proteome of TAM. For comparison, we included S100A8/A9 and TGFB1 (which were found in the proteome) as positive controls. All proteins analyzed were detected by flow cytometry, albeit in vastly variable fractions of cells (e.g., IL1B in nearly 100% of the cells, TGFBRIII in only 3%) ( Supplementary Fig. 2c , 2d and 2e).
Next, we studied the correlation between transcriptome and proteome for genes encoding growth factor/cytokine receptors and their ligands in a cell type-specific manner. Our transcriptomic analysis revealed mRNA expression of 181 genes encoding receptors and 209 genes encoding ligands ( Supplementary Fig. 3a Out of these expressed genes, 37 coding for growth factor/cytokine receptors (20.4%) and 44 coding for their ligands (22.0%) were also identified in the proteomes (Supplementary Fig. 3c and   d ). In the majority of cases, there was a positive correlation of mRNA and protein expression (Spearman ρ=0.3-1.0; Supplementary Fig. 5 and 6 ). Cell type-selective mRNA expression was higher for genes encoding ligands (n=74 expressed in all 3 cell types; 35.4%) than for genes encoding receptors (n=93; 51.4%).
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Analysis of the proteome of TU, TAM and TAT.
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(a) Expression of cell type-specific marker proteins in tumor cells (TU, n=9), tumor-associated macrophages (TAM, n=8) and tumor-associated T cells (TAT, n=8). Expression levels are based on LFQ intensity values calculated from mass spectrometry data. Three TAT samples with significant (see Materials and Methods) levels of tumor marker expression are marked as "contaminated" (triangles). For these 3 TAT samples, the sum of LFQ intensities of tumor marker proteins was higher than in the TU sample with the lowest sum of LFQ intensities of tumor markers (see Materials and Methods for details). These samples were excluded from the analysis of proteins upregulated in TU versus TAT (panel (c) 
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Comparison of transcriptomes and proteomes.
(a) Venn diagrams representing the number of detected mRNAs in transcriptomes (TPM>2) and proteins (with HGNC symbols) in proteomes of TU, TAM and TAT. The following sets of genes were analyzed: all genes ("all"); genes encoding secreted proteins ("secreted") or membrane proteins ("membrane"), both sets derived from ProteinAtlas as described in Materials and Methods; and genes not in the latter two groups ("intracellular"). Some genes (n=306) were assigned to both the "secreted" and "membrane" set. ITPKC  LAMB1  PALLD  SQRDL  STARD3NL  SUPT5H  TOE1   ANKRD27  APOBEC3G  CD44  CPVL  CYBA  ECH1  FLNC  GMPR 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 Comparison between the proteomes of tumor cells from HGSOC-associated ascites and ovarian tumor tissue. The combined proteome of TU, TAM, and TAT from ovarian cancer ascites (data from this study) was compared to the proteome of solid ovarian tumor tissue (Zhang et al, 2016) . This analysis yielded an overlap of 6,589 proteins. 597 proteins were exclusively found in cells isolated from ascites, while 2,581 proteins were exclusively found in solid ovarian tumor tissue. Those growth factors/cytokines and their respective receptors, which were detected in one of the two proteomes only (but not in both), are listed. ADIPOQ ANGPTL1 ANGPTL2 ANGPTL4 BMP1 CCL18 CCL21 CMTM3  CSF1 CTGF CXCL10 CXCL12 CXCL14 CXCL16 CXCL17 EFEMP1 EFNA1  EFNA5 EFNB2 FBRS FGFBP1 FST FSTL1 GREM1 HGF IGF1 IGF2BP1  IGFALS IGFBP3 IGFBP4 IGFBP5 IGFBP7 INHBA JAG1 LEFTY1 LEFTY2  MDK OGN PDGFC PDGFD PPBP PTN PYY S100A3 S100A7A S100B  SEMA3C SEMA3F SEMA4A SEMA4D SEMA5B SEMA7A SFRP1 SFRP2  SFRP4 SLIT2 SLIT3 SPP2 SST STC2 TGFB2 TGFB3 THBS2 THBS4  TNFSF13 Scheme depicting the contrasting roles of distinct TAM subsets in HGSOC biology. TAMsecreted mediators are grouped according to the data in Fig. 6 
Cytokines/growth factors in tumor tissue proteome only

